27/08/08
Oralair® Grasses 300 IR : Highly positive results in a pharmacodynamic study conducted in an allergen challenge chamber

Stallergenes S.A. announces the highly positive results of a new study conducted in an Allergen Challenge Chamber (ACC).

The study on Oralair® Grasses included 86 adult patients exposed to grass pollen challenge with different...

27/08/08
First Half Year 2008: a 19% increase in operating profit and net profit

The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financal statements:

10/07/08
Q2 2008 sales up 18%

1st half-year sales up 16%, revision upwards of 2008 sales growth guidance: ≥12%

24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses

Stallergenes has been granted with the market authorization in Germany for its sublingual desensitisation tablet Oralair® Grasses.

24/06/08
Video interview of Albert Saporta

View the interview of Stallergenes CEO

15/04/08
2008 1st quarter sales up 15%

First quarter sales continued to grow at a solid pace

12/03/08
2007 results

Further profit growth; Sales up 16%; Profit before R&D up 19%;

Net profit (Group share) up 12%; Acceleration of R&D expenditure

15/01/08
Quarterly information

2007: A further year of strong growth: up 16%

10/01/08
Implementation of a liquidity contract

Stallergenes has entrusted SG Securities Paris with the implementation of a liquidity contract

13/12/07
Partnership for producing mites recombinant allergens

Partnership agreement between Stallergenes and PROTEIN’EXPERT

28/11/07
Oralair® Grasses: Positive results of VO52.06 paediatric study

The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.

11/10/07
Quarterly information

3rd quarter (Q3) sales up 17%

9-month cumulative sales up 17%

28/08/07
2007 half-year results

Strong business growth +17%

Earnings per share up 30%

12/07/07
2007 1st half-year sales up 17%,Q2 sales up 13%

(€ millions) 2007 2006 07/06   % sales   % sales % change Southern Europe (1)23.2272.020.5371.813Other EU countries (2)7.6923.86.9124.211Other...

17/04/07
2007 1st quarter sales up 20%

(€ millions) 2007 % of sales 2006 % of sales07/ 06 % Change Southern Europe(1) 33,3278,327,5777,521Other EU countries8,0719,06,8019,119Other markets1,172,71,223,4(4)SLIT34,6381,427,6677,725SCIT6,1714,56,2717,6(2)Other...

15/03/07
Increase in operating profit and additional R&D efforts

The Board of Directors, meeting on 14 March 2007 under the chairmanship of Albert SAPORTA, approved the 2006 consolidated financial statements prepared in accordance with international accounting standards. Comparative 2005...

13/02/07
Stallergenes enters the Netherlands through a joint-venture agreement

Antony,France (Feb. 13, 2007) 'Stallergenes SA today announced that it has set up a joint-venture in the Netherlands in partnership with the Dutch company Sanmed B.V.

The agreement represents an important step forward in...

15/01/07
Strong 13% 2006 full-year growth,2006 4th quarter sales up 13%

€ millions 2006 2005 % increase Quarter 4 sales 37.46 33.14 13% France, including overseas dependencies19.3316.1819%Subsidiaries (1) 14.0913.306%Distributors (2)4.043.6610%Cumulative sales at end December 126.55 112.04 13%...